ArticleCancer chemotherapy and pharmacology2014

A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC).

Ana M Molina et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.